Developer docs
API playgroundTry for free, no card

Search company profiles

EpiEndo Pharmaceuticals

Full company profile

uuid0002iod

Namestring
EpiEndo Pharmaceuticals
Legal namestring
EpiEndo Pharmaceuticals
Websiteurl
epiendo.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Reykjavík, Iceland, developing oral therapeutics for chronic respiratory diseases with a primary focus on chronic obstructive pulmonary disease (COPD). The company operates as a semi-virtual organization with approximately 31 staff distributed across Iceland, Sweden, Denmark, and the UK. Its core technology is the Barriolides™ platform, a proprietary class of non-antibiotic macrolides designed to retain the anti-inflammatory and epithelial barrier-enhancing properties of macrolides while eliminating antimicrobial activity, thereby avoiding antimicrobial resistance (AMR) risk that limits long-term use of off-label antibiotic macrolides like azithromycin.

The company's lead asset is glasmacinal (formerly EP395), a first-in-class oral non-antibiotic macrolide that enhances host defense response to inhaled pathogens and reduces neutrophilic and eosinophilic inflammation. Glasmacinal completed successful Phase 1 (May 2022) and Phase 2a (April 2024) trials in COPD patients, demonstrating 66% relative reduction in sputum neutrophil elastase and 75% reduction in myeloperoxidase versus placebo with no detectable lung microbiome disruption. WHO assigned the INN 'glasmacinal' in December 2024, formally recognizing the new '-macinal' drug class. Beyond COPD, EpiEndo is extending its Barriolides™ platform into ulcerative colitis through the EpicoliX Project partnership with AlveoliX (lead candidate Enterothelin identified via organ-on-chip screening) and into asthma via a Lund University collaboration.

EpiEndo is pre-revenue with no commercial products and no established pricing. The company intends to monetize through future drug commercialization, most likely via licensing partnerships with pharmaceutical companies for distribution and sales of glasmacinal as a prescription medication. The company has raised approximately EUR 35 million in cumulative funding across grants, seed rounds, a EUR 20 million Series A (August 2021), and a EUR 9 million convertible bond (January 2026), with major investors including Flerie Invest, Iðunn Venture Fund, the EIC Fund, and ABC Venture.

Short descriptiontext

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing glasmacinal, a first-in-class oral non-antibiotic macrolide from its Barriolides™ platform, for the treatment of COPD and other chronic respiratory and inflammatory diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersReykjavík, Iceland
HQ citystring
Reykjavík
HQ countrystring
Iceland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-antibiotic macrolides, chronic respiratory therapeutics, COPD drug development, epithelial barrier therapeutics, anti-inflammatory pharmaceuticals
Industry2 codes
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Respiratory Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company developing novel therapeutics for chronic respiratory diseases. Revenue will be generated through eventual drug commercialization, likely via licensing partnerships or direct sales upon regulatory approval.

epiendo.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Barriolides
Description

New class of orally available macrolides with reduced antimicrobial resistance (AMR) potential. These are epithelial barrier-enhancing, anti-inflammatory drug candidates developed for chronic respiratory diseases and other inflammatory indications.

epiendo.com
+1 more record
Core offering1 text field

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral, non-antibiotic macrolide drugs for chronic respiratory diseases, with lead candidate glasmacinal (EP395) targeting chronic obstructive pulmonary disease (COPD). The company is built around its proprietary Barriolides™ platform, a new class of macrolide derivatives designed to retain anti-inflammatory and epithelial barrier-enhancing properties while eliminating antimicrobial resistance risk. The pipeline also includes Enterothelin, a Barriolide candidate for ulcerative colitis identified through organ-on-chip screening.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 66% relative reduction in sputum neutrophil elastase with EP395 vs placebo
+3 more records
Product overview1 text field

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of orally available macrolide therapeutics. The core product is glasmacinal (EP395), the first drug candidate in the company's proprietary Barriolides™ platform—a new class of non-antibiotic macrolides with reduced antimicrobial resistance potential that enhance epithelial barrier function and provide anti-inflammatory effects. The lead indication is chronic obstructive pulmonary disease (COPD). The company is also developing Enterothelin, another Barriolide candidate, for ulcerative colitis through its EpicoliX Project partnership with AlveoliX. The Barriolides™ platform represents first-in-class oral therapeutics for chronic respiratory diseases and other inflammatory conditions.

Product and service2 records
1Glasmacinal (EP395)
CategoryRespiratory pharmaceutical - COPD lead candidate
Description

Oral anti-inflammatory macrolide drug candidate (previously EP395) for chronic obstructive pulmonary disease (COPD). First candidate in the Barriolides™ class with negligible antimicrobial activity but anti-inflammatory and immunomodulatory properties; enhances host defense response to inhaled pathogens and strengthens epithelial barrier function.

2Enterothelin
CategoryInflammatory bowel disease pharmaceutical candidate
Description

Barriolide compound developed as a lead candidate for ulcerative colitis treatment through the EpicoliX Project partnership with AlveoliX. A first-in-class therapy addressing the underlying cause of UC by enhancing colon epithelium and reducing inflammation and ulcer formation.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-06-04
Description

Collaboration investigating glasmacinal's effects on antiviral responses in bronchial epithelial cells from asthma patients.

2Fraunhofer Institute for Toxicology and Experimental Medicine
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-31
Description

Conduction of LPS challenge clinical trials with EP395/glasmacinal in healthy volunteers under Prof Jens Hohlfeld's leadership.

epiendo.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-04-21
Description

Swedish CRO conducting drug-drug interaction studies with EP395, led by Dr Björn Schultze.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-01
Description

Collaboration with Prof Clive Page's team on preclinical research on EP395 effects on airway inflammation and epithelial barrier function.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-13
Description

Clinical trial site for first-in-human Phase 1 trial of EP395, led by Prof Dave Singh. Continues as principal investigator site for subsequent clinical trials.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-05
Description

EpicoliX Project - Eureka Eurostars funded collaboration to develop ulcerative colitis treatment using AlveoliX's AXGut-on-Chip technology combined with EpiEndo's Barriolide compounds. Led to identification of Enterothelin as lead UC candidate.

7Recipharm
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2014-10-11
Description

Partnership with Swedish CDMO for synthesis of novel compounds. Recipharm is a leading Contract Development and Manufacturing Organisation that brings pharmaceutical manufacturing expertise to EpiEndo's compound development.

epiendo.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Foundational research origin - EpiEndo's technology is based on over 20 years of research at the University of Iceland, including Stem Cell Research Unit collaboration.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage company developing iSPERSE-based inhaled therapeutics for respiratory infections and inflammatory diseases. Comparable as a small respiratory biotech with novel delivery technology.

TypeBroad incumbent
Description

Major pharmaceutical company with leading COPD franchise (Trelegy Ellipta, Anoro, Incruse) and significant respiratory R&D capabilities. Most relevant broad incumbent for understanding COPD competitive dynamics and potential acquirer profile.

TypeBroad incumbent
Description

Major pharmaceutical company with leading COPD franchise (Breztri Aerosphere, Symbicort, Trixeo). Most relevant broad incumbent as potential licensing/acquisition partner given established respiratory commercial footprint.

4Boehringer Ingelheim
TypeBroad incumbent
Description

Major pharmaceutical company with leading COPD franchise (Spiriva, Stiolto, Striverdi) and respiratory pipeline. Comparable as broad incumbent shaping the COPD therapeutic landscape.

TypeEmerging player
Description

UK-based biopharma developing therapies for respiratory diseases including COPD, with focus on epithelial ion channel modulation. Comparable for shared interest in epithelial-targeted respiratory therapeutics.

TypeBroad incumbent
Description

Dupixent (dupilumab) recently expanded into COPD with Phase 3 success, marking entry of IL-4/IL-13 biologic into the space. Comparable as broad incumbent now competing in COPD with biologic and broad respiratory portfolio.

TypeDirect peer
Description

Clinical-stage biotech focused on inflammatory diseases with pipeline including respiratory indications. Comparable as a small clinical-stage company developing anti-inflammatory therapeutics.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing ensifentrine, an inhaled dual PDE3/PDE4 inhibitor for COPD maintenance therapy. Most directly comparable peer as a late clinical-stage respiratory biotech targeting COPD with a novel mechanism.

TypeDirect peer
Description

Clinical-stage biopharma developing therapies for rare respiratory diseases including alpha-1 antitrypsin deficiency. Similar stage and business model to EpiEndo as a clinical-stage respiratory-focused biotech with novel mechanisms.

TypeDirect peer
Description

Clinical-stage biopharma developing inhaled therapies for respiratory diseases including COPD and pulmonary infections. Comparable as a small-cap respiratory biotech with a novel drug delivery platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EpiEndo Pharmaceuticals

Respiratory Pharmaceuticalsepiendo.com

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing glasmacinal, a first-in-class oral non-antibiotic macrolide from its Barriolides™ platform, for the treatment of COPD and other chronic respiratory and inflammatory diseases.

What EpiEndo Pharmaceuticals does

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Reykjavík, Iceland, developing oral therapeutics for chronic respiratory diseases with a primary focus on chronic obstructive pulmonary disease (COPD). The company operates as a semi-virtual organization with approximately 31 staff distributed across Iceland, Sweden, Denmark, and the UK. Its core technology is the Barriolides™ platform, a proprietary class of non-antibiotic macrolides designed to retain the anti-inflammatory and epithelial barrier-enhancing properties of macrolides while eliminating antimicrobial activity, thereby avoiding antimicrobial resistance (AMR) risk that limits long-term use of off-label antibiotic macrolides like azithromycin.

The company's lead asset is glasmacinal (formerly EP395), a first-in-class oral non-antibiotic macrolide that enhances host defense response to inhaled pathogens and reduces neutrophilic and eosinophilic inflammation. Glasmacinal completed successful Phase 1 (May 2022) and Phase 2a (April 2024) trials in COPD patients, demonstrating 66% relative reduction in sputum neutrophil elastase and 75% reduction in myeloperoxidase versus placebo with no detectable lung microbiome disruption. WHO assigned the INN 'glasmacinal' in December 2024, formally recognizing the new '-macinal' drug class. Beyond COPD, EpiEndo is extending its Barriolides™ platform into ulcerative colitis through the EpicoliX Project partnership with AlveoliX (lead candidate Enterothelin identified via organ-on-chip screening) and into asthma via a Lund University collaboration.

EpiEndo is pre-revenue with no commercial products and no established pricing. The company intends to monetize through future drug commercialization, most likely via licensing partnerships with pharmaceutical companies for distribution and sales of glasmacinal as a prescription medication. The company has raised approximately EUR 35 million in cumulative funding across grants, seed rounds, a EUR 20 million Series A (August 2021), and a EUR 9 million convertible bond (January 2026), with major investors including Flerie Invest, Iðunn Venture Fund, the EIC Fund, and ABC Venture.

EpiEndo Pharmaceuticals firmographics

Firmographics
Name
EpiEndo Pharmaceuticals
Legal name
EpiEndo Pharmaceuticals
Website
https://epiendo.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing glasmacinal, a first-in-class oral non-antibiotic macrolide from its Barriolides™ platform, for the treatment of COPD and other chronic respiratory and inflammatory diseases.
Ownership category
akta.pro rank

EpiEndo Pharmaceuticals industry classification

Industry
Product category
Respiratory Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Non-antibiotic macrolides
  • Chronic respiratory therapeutics
  • COPD drug development
  • Epithelial barrier therapeutics
  • Anti-inflammatory pharmaceuticals

Where EpiEndo Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Reykjavík
HQ country
Iceland
HQ region
Europe

Offices2 records

Markets served

EpiEndo Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Others

Revenue model

  1. Pharmaceutical Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing novel therapeutics for chronic respiratory diseases. Revenue will be generated through eventual drug commercialization, likely via licensing partnerships or direct sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

EpiEndo Pharmaceuticals product offering

Product offering

Core offering

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral, non-antibiotic macrolide drugs for chronic respiratory diseases, with lead candidate glasmacinal (EP395) targeting chronic obstructive pulmonary disease (COPD). The company is built around its proprietary Barriolides™ platform, a new class of macrolide derivatives designed to retain anti-inflammatory and epithelial barrier-enhancing properties while eliminating antimicrobial resistance risk. The pipeline also includes Enterothelin, a Barriolide candidate for ulcerative colitis identified through organ-on-chip screening.

Product overview

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of orally available macrolide therapeutics. The core product is glasmacinal (EP395), the first drug candidate in the company's proprietary Barriolides™ platform—a new class of non-antibiotic macrolides with reduced antimicrobial resistance potential that enhance epithelial barrier function and provide anti-inflammatory effects. The lead indication is chronic obstructive pulmonary disease (COPD). The company is also developing Enterothelin, another Barriolide candidate, for ulcerative colitis through its EpicoliX Project partnership with AlveoliX. The Barriolides™ platform represents first-in-class oral therapeutics for chronic respiratory diseases and other inflammatory conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • Barriolides: New class of orally available macrolides with reduced antimicrobial resistance (AMR) potential. These are epithelial barrier-enhancing, anti-inflammatory drug candidates developed for chronic respiratory diseases and other inflammatory indications.
  • glasmacinal

Products and services

  • Glasmacinal (EP395) Oral anti-inflammatory macrolide drug candidate (previously EP395) for chronic obstructive pulmonary disease (COPD). First candidate in the Barriolides™ class with negligible antimicrobial activity but anti-inflammatory and immunomodulatory properties; enhances host defense response to inhaled pathogens and strengthens epithelial barrier function.
  • Enterothelin Barriolide compound developed as a lead candidate for ulcerative colitis treatment through the EpicoliX Project partnership with AlveoliX. A first-in-class therapy addressing the underlying cause of UC by enhancing colon epithelium and reducing inflammation and ulcer formation.

Quantifiable outcome

  • 66% relative reduction in sputum neutrophil elastase with EP395 vs placebo
  • +3 more outcomes

Companies that use EpiEndo Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles3 records

EpiEndo Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

EpiEndo Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • Lund UniversityminorStrategic or Co-development Partner · 4 June 2024Collaboration investigating glasmacinal's effects on antiviral responses in bronchial epithelial cells from asthma patients.
  • Fraunhofer Institute for Toxicology and Experimental MedicinecoreStrategic or Co-development Partner · 31 August 2022Conduction of LPS challenge clinical trials with EP395/glasmacinal in healthy volunteers under Prof Jens Hohlfeld's leadership.
  • CTC Clinical Trial Consultants ABminorStrategic or Co-development Partner · 21 April 2022Swedish CRO conducting drug-drug interaction studies with EP395, led by Dr Björn Schultze.
  • King's College LondoncoreStrategic or Co-development Partner · 1 September 2021Collaboration with Prof Clive Page's team on preclinical research on EP395 effects on airway inflammation and epithelial barrier function.
  • Medicines Evaluation Unit (MEU), ManchestercoreStrategic or Co-development Partner · 13 April 2021Clinical trial site for first-in-human Phase 1 trial of EP395, led by Prof Dave Singh. Continues as principal investigator site for subsequent clinical trials.
  • AlveoliXcoreStrategic or Co-development Partner · 5 March 2021EpicoliX Project - Eureka Eurostars funded collaboration to develop ulcerative colitis treatment using AlveoliX's AXGut-on-Chip technology combined with EpiEndo's Barriolide compounds. Led to identification of Enterothelin as lead UC candidate.
  • RecipharmcoreTechnology or Integration · 11 October 2014Partnership with Swedish CDMO for synthesis of novel compounds. Recipharm is a leading Contract Development and Manufacturing Organisation that brings pharmaceutical manufacturing expertise to EpiEndo's compound development.
  • University of IcelandcoreStrategic or Co-development PartnerFoundational research origin - EpiEndo's technology is based on over 20 years of research at the University of Iceland, including Stem Cell Research Unit collaboration.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

EpiEndo Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Inhalon Biopharma: Clinical-stage company developing iSPERSE-based inhaled therapeutics for respiratory infections and inflammatory diseases. Comparable as a small respiratory biotech with novel delivery technology.
  • Avalo Therapeutics: Clinical-stage biotech focused on inflammatory diseases with pipeline including respiratory indications. Comparable as a small clinical-stage company developing anti-inflammatory therapeutics.
  • Verona Pharma: Clinical-stage biopharmaceutical company developing ensifentrine, an inhaled dual PDE3/PDE4 inhibitor for COPD maintenance therapy. Most directly comparable peer as a late clinical-stage respiratory biotech targeting COPD with a novel mechanism.
  • Mereo BioPharma: Clinical-stage biopharma developing therapies for rare respiratory diseases including alpha-1 antitrypsin deficiency. Similar stage and business model to EpiEndo as a clinical-stage respiratory-focused biotech with novel mechanisms.
  • Pulmatrix: Clinical-stage biopharma developing inhaled therapies for respiratory diseases including COPD and pulmonary infections. Comparable as a small-cap respiratory biotech with a novel drug delivery platform.

Broad incumbents

  • GSK: Major pharmaceutical company with leading COPD franchise (Trelegy Ellipta, Anoro, Incruse) and significant respiratory R&D capabilities. Most relevant broad incumbent for understanding COPD competitive dynamics and potential acquirer profile.
  • AstraZeneca: Major pharmaceutical company with leading COPD franchise (Breztri Aerosphere, Symbicort, Trixeo). Most relevant broad incumbent as potential licensing/acquisition partner given established respiratory commercial footprint.
  • Boehringer Ingelheim: Major pharmaceutical company with leading COPD franchise (Spiriva, Stiolto, Striverdi) and respiratory pipeline. Comparable as broad incumbent shaping the COPD therapeutic landscape.
  • Sanofi/Regeneron: Dupixent (dupilumab) recently expanded into COPD with Phase 3 success, marking entry of IL-4/IL-13 biologic into the space. Comparable as broad incumbent now competing in COPD with biologic and broad respiratory portfolio.

Emerging players

  • Enterprise Therapeutics: UK-based biopharma developing therapies for respiratory diseases including COPD, with focus on epithelial ion channel modulation. Comparable for shared interest in epithelial-targeted respiratory therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

EpiEndo Pharmaceuticals social profiles

Digital presence

EpiEndo Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EpiEndo Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles19 records

EpiEndo Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EpiEndo Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EpiEndo Pharmaceuticals

What does EpiEndo Pharmaceuticals do?

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral, non-antibiotic macrolide drugs for chronic respiratory diseases, with lead candidate glasmacinal (EP395) targeting chronic obstructive pulmonary disease (COPD). The company is built around its proprietary Barriolides™ platform, a new class of macrolide derivatives designed to retain anti-inflammatory and epithelial barrier-enhancing properties while eliminating antimicrobial resistance risk. The pipeline also includes Enterothelin, a Barriolide candidate for ulcerative colitis identified through organ-on-chip screening.

Is EpiEndo Pharmaceuticals a public or private company?

EpiEndo Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was EpiEndo Pharmaceuticals founded?

EpiEndo Pharmaceuticals was founded in 2014. It employs 11 to 50 people.

Where is EpiEndo Pharmaceuticals based?

EpiEndo Pharmaceuticals is headquartered in Reykjavík, Iceland, in the Europe region.

How does EpiEndo Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Drug Development and Commercialization.

Who are EpiEndo Pharmaceuticals's main competitors?

Direct peers on record are Inhalon Biopharma, Avalo Therapeutics, Verona Pharma, Mereo BioPharma and Pulmatrix. Broad incumbents are GSK, AstraZeneca, Boehringer Ingelheim and Sanofi/Regeneron. Enterprise Therapeutics is listed as an emerging player.

Does EpiEndo Pharmaceuticals have an API?

No public API is recorded for EpiEndo Pharmaceuticals.

What industry is EpiEndo Pharmaceuticals in?

EpiEndo Pharmaceuticals's product category is Respiratory Pharmaceuticals. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireEpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patientsEpiEndo Pharmaceuticals reported a randomized, double-blind placebo-controlled trial of glasmacinal (EP395) in stable COPD patients, which was well-tolerated and reduced neutrophilic inflammation in sputum. The drug had no detectable impact on the lung microbiome, supporting its minimal antimicrobial activity and reduced antimicrobial resistance potential. The company plans an exacerbation reduction trial in COPD patients.GlobeNewswireEpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patientsEpiEndo Pharmaceuticals published clinical trial results for glasmacinal (EP395) in ERJ Open Research, reporting that the novel macrolide was well-tolerated and reduced neutrophilic inflammation in stable COPD patients over 12 weeks. The trial found no detectable impact on lung microbiome, supporting the drug's reduced antimicrobial resistance potential, while more patients treated with glasmacinal showed clinically meaningful symptom improvements versus placebo. The company is now planning a larger exacerbation reduction trial in COPD patients who continue to experience exacerbations despite standard of care therapy.Business Wire BlogEpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for the treatment of COPDEpiEndo Pharmaceuticals closed a €20 million Series A funding round led by Flerie Invest and Iðunn Venture Fund, with participation from ABC Ventures and the European Innovation Council Fund. The capital will advance clinical development of its lead compound EP395 through Phase IIa trials for the treatment of chronic obstructive pulmonary disease (COPD).Nordic 9EpiEndo Pharmaceuticals secured €4.5 million in equity and grant financing.EpiEndo Pharmaceuticals raised €4.5 million in equity and grant financing, with €2 million in seed equity and €2.5 million from the European Innovation Council. The funds will advance a candidate drug through GLP tox and API development toward Phase I. This is the company's fourth seed round.